Together, these results show that the addition of IL-2 can overcome lung tumor primary resistance to systemic IL12-MSA monotherapy, that combined IL-2 and IL-12 orchestrate distinct effects on CD8+ T cells and Tregs to induce tumor control, and that the dose-limiting toxicity of this combination can be overcome by using engineered cytokine variants. This evidence concerns the gene IL2 and neoplasm.